Business
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public offering price of US$6.25 per share. The Company has also granted t
About this update from Optimi Health Corp.
[{"type":"text","content":"Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"","length":85,"tagName":"p"},{"type":"text","content":"VANCOUVER, BC, May 20, 2026 /CNW/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public offering price of US$6.25 per share. The Company has also granted the Underwriter (as defined below) the option to purchase up to an additional 360,000 common shares. The common shares are expected to begin trading on the Nasdaq Capital Market on May 20, 2026 under the symbol "OPTH."","length":798,"tagName":"p"},{"type":"image","alt":"Optimi Health Corp Corporate Logo (CNW Group/Optimi Health Corp)","displaySize":"","headline":null,"caption":"Optimi Health Corp Corporate Logo (CNW Group/Optimi Health Corp)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":105,"url":"https://media.zenfs.com/en/prnewswire.com/350608d4f90bd94c6f08417e9d291e96"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ro0RUnb.fwCRwFTeqQ8U8A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NQ--/https://media.zenfs.com/en/prnewswire.com/350608d4f90bd94c6f08417e9d291e96","width":400,"height":105},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/VvbXBpRRMhvFrpLzhqjrrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE2OA--/https://media.zenfs.com/en/prnewswire.com/350608d4f90bd94c6f08417e9d291e96","width":400,"height":105}},"href":"https://mma.prnewswire.com/media/2984049/Optimi_Health_Corp_Optimi_Health_Announces_Pricing_of_Oversubscr.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The gross proceeds from the Offering, before deducting underwriting discounts and commissions and other estimated Offering expenses payable by the Company, are expected to be approximately US$15 million, excluding any exercise of the underwriter's option to purchase additional shares. The Offering is expected to close on or about May 21, 2026, subject to the satisfaction of customary closing condi...